Skip to main content
Joseph Antin, MD, Hematology, Boston, MA

JosephHarryAntinMD

Hematology Boston, MA

Hematologic Oncology

Professor of Medicine, Dana-Farber Cancer Institute

Dr. Antin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Antin's full profile

Already have an account?

  • Office

    44 Binney St
    # Dana-Far
    Boston, MA 02115
    Phone+1 617-632-3667
    Fax+1 617-632-5175

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1981 - 1983
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 1978 - 1981
  • Weill Cornell Medicine
    Weill Cornell MedicineClass of 1978

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1986 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Boston Magazine Castle Connolly, 2008-2013
  • America's Top Doctors for Cancer Castle Connolly, 2005-2013
  • Boston Herald Castle Connolly, 2005
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Small-Molecule BCL6 Inhibitor Effectively Treats Mice with Non-Sclerodermatous Chronic Graft-Versus-Host Disease  
    Joseph H Antin, Bruce Blazar, Leo Luznik, John Koreth, Ivan Maillard, Robert J Soiffer, James E Bradner, Jonathan S Serody, Jerome Ritz, Blood

Abstracts/Posters

  • Improved Outcomes with Cyclophosphamide/Total Body Irradiation 14 Gy Compared to Cyclophosphamide/Total Body Irradiation 12 Gy in Patients with Acute Lymphoblastic Leu...
    Joseph H. Antin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease
    Joseph H. Antin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • A Phase II Trial to Compare Allogeneic Transplant Vs. Standard of Care for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Pr...
    Joseph H. Antin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-Cell Lymphoma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • ASBMT News
    ASBMT NewsOctober 13th, 2018
  • Genetic Profiling Can Guide Stem Cell Transplantation for Patients with Myelodysplastic Syndrome, Study Finds
    Genetic Profiling Can Guide Stem Cell Transplantation for Patients with Myelodysplastic Syndrome, Study FindsFebruary 9th, 2017
  • Genetic Profiling Can Guide Stem Cell Transplantation for Patients with Myelodysplastic Syndrome, Study Finds
    Genetic Profiling Can Guide Stem Cell Transplantation for Patients with Myelodysplastic Syndrome, Study FindsFebruary 8th, 2017
  • Join now to see all

Grant Support

  • A Randomized Trial Of Tac/Mtx/Bortezomib VS Tac/Mtxplacebo In Allogeneic HSCTNational Heart, Lung, And Blood Institute2011
  • Novel Approaches To Graft-Versus-Host Disease PreventionNational Cancer Institute2009–2011
  • Mechanisms Of GVHDNational Cancer Institute2009–2011
  • Administrative CoreNational Cancer Institute2009–2011
  • Random Trial Of CD8 T-Cell Depletion In PBSC TransplantationNational Heart, Lung, And Blood Institute2006–2010
  • Novel Approaches To Ghvd PreventionNational Heart, Lung, And Blood Institute2007
  • Mechanisms Of GVHDNational Heart, Lung, And Blood Institute2003–2007
  • Randomized Trial Of CD8 T-Cell Depletion In PBSC Transp*National Heart, Lung, And Blood Institute2001–2005
  • Use Of Unrelated Donors For Bone Marrow TransplantationNational Center For Research Resources1997–1999
  • Phlebotomy For Research Studies After Marrow TransplantationNational Center For Research Resources1997–1999
  • Core--Clinical Bone Marrow Transplant ProgramNational Cancer Institute1997
  • Novel Therapy For Chronic Myelogenous LeukemiaNational Cancer Institute1993–1996

Professional Memberships